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ARTICLE
A high-throughput Galectin-9 imaging assay for
quantifying nanoparticle uptake, endosomal escape
and functional RNA delivery
Michael J. Munson 1✉, Gwen O’Driscoll 1, Andreia M. Silva2, Elisa Lázaro-Ibáñez 1, Audrey Gallud3,
John T. Wilson 4, Anna Collén5, Elin K. Esbjörner 3 & Alan Sabirsh 1✉
RNA-based therapies have great potential to treat many undruggable human diseases.
However, their efficacy, in particular for mRNA, remains hampered by poor cellular delivery
and limited endosomal escape. Development and optimisation of delivery vectors, such as
lipid nanoparticles (LNPs), are impeded by limited screening methods to probe the intra-
cellular processing of LNPs in sufficient detail. We have developed a high-throughput ima-
ging-based endosomal escape assay utilising a Galectin-9 reporter and fluorescently labelled
mRNA to probe correlations between nanoparticle-mediated uptake, endosomal escape
frequency, and mRNA translation. Furthermore, this assay has been integrated within a
screening platform for optimisation of lipid nanoparticle formulations. We show that
Galectin-9 recruitment is a robust, quantitative reporter of endosomal escape events induced
by different mRNA delivery nanoparticles and small molecules. We identify nanoparticles
with superior escape properties and demonstrate cell line variances in endosomal escape
response, highlighting the need for fine-tuning of delivery formulations for specific
applications.
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O ligonucleotide therapies (including siRNA, antisense oli-gos (ASOs) and mRNA) are therapeutic interventionsthat target or deliver protein-encoding mRNA; these can
therefore modulate, with high specificity, targets that are con-
sidered undruggable by classical small-molecule approaches or
other traditional modalities1,2. Hydrophilic oligonucleotides
cannot be readily taken up across cellular membranes and are
prone to degradation by endogenous nucleases, therefore the use
of delivery vectors for both protection and delivery is required3.
Delivery systems such as lipid nanoparticles (LNPs) or polymeric
nanoparticles (PNPs) are being explored in an attempt to bolster
the intracellular delivery of oligonucleotides, however, these sys-
tems still have disadvantages concerning safety, stability and most
importantly delivery efficacy4. Despite progress in the develop-
ment and design of LNP and PNP vectors5, the delivery efficacy
of short oligonucleotides using synthetic nanoparticles remains
poor. It is estimated that only 1.5–3.5% of siRNA cargo taken up
by cells reaches the cytoplasm, with approximately half of the
nucleotide cargo released when an endosomal disruption event
does occur6,7. Oligonucleotides such as mRNA are considerably
larger (~600–10,000 kDa) than ASOs/siRNA (~4–14 kDa), likely
diminishing delivery yields even further5. Endosomal escape is
therefore one of the most substantial bottlenecks for successful
oligonucleotide delivery. Improving endosomal release is a key
driver for delivery system design and will be of great importance
for the further development of oligonucleotide therapeutics,
particularly for treatments that require high therapeutic protein
levels.
LNPs are of particular interest as delivery vectors due to their
relative stability, low toxicity and ease of large-scale preparation8.
However, optimising the chemical and physical features of these
entities to improve functional delivery is a complex task. LNPs are
typically comprised of four major lipid components: an ionisable
lipid, a sterol, a phospholipid and a lipidated polyethylene glycol
(PEG). The ionisable lipid has been the primary subject of
development with combinatorial libraries often used to identify
new lipids9,10. However, the undeniable importance of other
components such as the sterol or the PEG-lipid for modulating
uptake, improving pharmacokinetics or modifying the particle’s
corona composition is being increasingly appreciated11–14.
Optimising the relative abundance of each component can further
modulate potency by up to sevenfold15, but to fully explore all of
these parameters requires fast and robust screening assays.
Despite the central importance of endosomal escape, there are
currently limited established options to evaluate this event in
living cells16.
Members of the Galectin (GAL/LGALS) family of proteins
have been exploited as reporters of endosomal escape in a variety
of contexts. Galectins are primarily expressed in the cytosol and
contain carbohydrate recognition domains (CRDs) that bind to β-
galactoside sugars17. Galectins can be recruited to endosomes
when membrane damage exposes β-galactosides on the inner
leaflet of the endosomal membrane to the cytosol18. Point
mutations that strongly reduce the binding affinity of the CRD
also prevent endosomal relocalisation of GAL318–20. The expo-
sure of β-galactosides often occurs during host-pathogen inter-
actions as a method of identifying damaged cellular membranes
and aims to assist in the clearance of pathogens21,22. GAL8/9 are
also robustly recruited to sites of endosomal damage in response
to artificial delivery vehicles such as LNPs or PNPs that induce
endosomal escape as a mechanism of nucleotide cargo
delivery7,23. Endosomal escape induced localisation of GAL8 was
shown to recruit autophagy adaptors as part of a clearance
response against Salmonella and therefore forms an important
part of cellular host-defence22. GAL9 recruitment has no similarly
reported perturbing effects on normal cellular function and was
recently reported to evoke a greater recruitment response to
endolysosome damage than GAL3 or GAL824.
To address the basic limitations of characterising nanoparticle
function, we have developed a GAL9 based endosomal escape
imaging assay to allow time-lapse live-cell recordings of endo-
somal damage events. In combination with fluorescently labelled
nanoparticles, this single assay allows a complete overview of
nanoparticle trafficking from cellular uptake to endosomal escape
and ultimately mRNA translation to functional protein whilst
also evaluating potential cellular toxicity within a high-
throughput format. We first demonstrate that this assay has a
large signal window for the detection of endosomal escape events,
confirming its suitability as a screening assay. We subsequently
validate GAL9 recruitment in response to cell treatments with
small molecules, LNPs and PNPs and highlight cell line-specific
differences in sensitivity to endosomal escape. Finally, we
demonstrate that this assay can be combined with robotic LNP
formulation, allowing extensive and rapid screening of nano-
particle formulations across multiple, biologically relevant
parameters.
Results
Generation of mCherry-Galectin9 reporter cells. We generated
four stable mCherry-GAL9 reporter expression cell lines using the
ObLiGaRe zinc-finger nuclease (ZFN) knock-in strategy25. Cell
lines were transiently transfected with an AAVS1-targeting ZFN
plasmid and a donor construct encoding a puromycin resistance
gene and mCherry-GAL9 under the E1α promoter (Fig. 1a).
Positively integrated cells were selected with puromycin and flow-
sorted into pools with similar mCherry-GAL9 expression levels
(Supplementary Fig. 1a, b). Gene copy number analysis of HepG2
cells revealed on average ~2.3 integrated copies (Supplementary
Fig. 2) of the mCherry-GAL9 reporter compared to HeLa (2
copies), NCI-H358 (2.9 copies) or Huh7 (3.5 copies) (Fig. 1b).
The integration site was verified using primers to amplify between
the AAVS1 locus and the reporter sequence, yielding the expected
251 bp product (Fig. 1c). Cell expression of the mCherry-GAL9
protein was verified by western blotting using an α-mCherry
antibody for detection (Fig. 1d). Two prominent bands were
observed, corresponding to full-length (~70 kDa) and truncated
(~50 kDa) mCherry-GAL9 (consistent with the loss of GAL9’s C-
terminal CRD (~20 kDa) due to protease cleavage26). Cells
modified to express mCherry-GAL9 exhibited generally diffuse
cytosolic mCherry staining under standard growth conditions
(Fig. 1e). Comparison of the cellular mCherry fluorescence
intensity by microscopy (Fig. 1f) supported the observations by
western blot that HepG2 and NCI-H358 cells expressed higher
levels of protein than HeLa and Huh7 cells (Fig. 1d, f). This
suggests that cell-lineage related differences in reporter protein
abundance exist that are not directly due to copy number var-
iation but may arise from differential regulation of galectin traf-
ficking and secretion27. The protein abundance, however, was not
decisive for assay function (see following).
mCherry-GAL9 is recruited to small molecule induced damage.
To validate that mCherry-GAL9 can be recruited to sites of
endolysosome damage, we exposed Huh7 mCherry-GAL9 cells to
small molecules known to induce endomembrane disruption
(Fig. 2a). We first used chloroquine, a cationic amphiphilic drug
(CAD) that accumulates in late endosomal compartments and
was recently used by Du Rietz et al. to study endosome rupture in
GFP-GAL9 expressing HeLa cells24,28. Following administration
of chloroquine, we observed dose-dependent induction of large
mCherry-GAL9 positive structures with a maximal response after
8–12 h of treatment and at ~60–80 µM, consistent with the
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positive response obtained by Du Rietz et al. (Fig. 2b, c)24. We
then tested three small molecules from a structurally related
family (UNC10217938A, UNC2383, and UNC4267 - Fig. 2a, b)
which were previously identified to enhance splice-switching
oligonucleotide and ASO delivery by inducing endomembrane
permeabilisation29,30. The response to UNC compounds was
rapid with maximal mCherry-GAL9 recruitment occurring at
1–3 h post-dosing (Fig. 2c); furthermore, the effect was seen at a
much lower dose (0–15 µM) compared to chloroquine. UNC2383
was the most potent compound with the induction of large
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Fig. 1 Generation of mCherry-GAL9 knock-in cell lines. a Knock-In strategy for mCherry-GAL9. Reporter plasmid contains analogous zinc finger nuclease
(ZFN) sites to AAVS1 locus. Co-transfection with an AAVS1 targeted ZFN induces a double-strand break and a non-homologous end-joining repair
mechanism, resulting in mCherry-GAL9 insertion under an EF1α promoter with a puromycin selection cassette. b Average copy number of puromycin
genomic insertions per cell determined by droplet digital PCR from n= 6 replicates, normalised to the reference gene AP3B1, as an indirect measurement of
mCherry-GAL9 insertions. c Representative agarose gel of the amplicon spanning the AASV1 locus and the donor mCherry-GAL9 donor vector, confirming
the insertion of the construct at the expected genomic location. Molecular weight (base-pairs, bp) of standards is indicated next to the gel. dWestern blot of
stably integrated mCherry-GAL9 cell lines for indicated proteins and non-transfected cell controls, 40 µg per lane. e Fluorescence images of Huh7, HepG2,
HeLa and NCI-H358 cells ± insertion of the mCherry-GAL9 reporter under normal growth conditions, scale bar= 20 µm. Note: LUTs between cell lines vary
(± mCherry-GAL9 reporter are matched), this is intended for clarity of GAL9 signal within cells. See (f) for true fluorescent intensity. f Quantitation of
cellular mCherry fluorescence intensity from reporter lines. Values are normalised means from n= 3 independent experiments ± SEM.
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numbers of small mCherry-GAL9 structures from 1.25 μM
(Fig. 2d). Our observations match both the timescale and the
required doses to achieve functional improvement of oligonu-
cleotide delivery reported previously for UNC2383 and supports
that this effect is indeed functionally linked to endosome
damage31. Simultaneously, we inferred cellular toxicity from
nuclear condensation that leads to smaller and more intense
Hoechst stained nuclear structures32. All compounds tested eli-
cited partial cellular toxicity that correlated with the level of
GAL9 recruitment (Fig. 2d). The ability to utilise nuclear
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Fig. 2 Small Molecules induce mCherry-GAL9 recruitment. a Chemical structures of chloroquine and UNC compounds b Representative images of Huh7
mCherry-GAL9 cells following 2 h incubation with indicated small molecules and doses, scale bar= 20 µm. c Kinetic analysis of mCherry-GAL9 puncta
formed across 0–12 h of incubation with indicated compounds and doses, values represent normalised means ± SEM from n= 3 independent experiments.
d Comparison of mCherry-GAL9 puncta induced (Orange line - 8 h chloroquine, 2 h UNC compounds) to cell survival (Grey line - 12 h post-dosing,
determined by Hoechst morphology) relative to the compound dose in Huh7 mCherry-GAL9 cells. Lines represent mean values from n= 3 independent
experiments.
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morphology and intensity to infer toxicity for simultaneous
evaluation of compound safety is useful for future screening of
compound libraries to identify novel small molecules that can
induce endosomal escape with improved safety profiles.
Our data demonstrate that the mCherry-GAL9 recruitment
assay can sensitively detect differences in the endosomal
damaging potencies of small molecule compounds and that their
effect does not require the presence of oligonucleotides. We next
determined the robustness of the mCherry-GAL9 recruitment
assay in Huh7 cells by calculating the Z’ factor in response to
UNC2383 treatment at 10 µM. The Z’ Factor is a measure of
separation between the minimum (vehicle) and maximum
response (UNC2383 10 µM) often used in the development of
screening assays33. The Z’ factor for Huh7 cells was calculated as
+0.76; assays rated above +0.5 are classified as excellent
screening assays33. This validates that a large signal window
exists and that the mCherry-GAL9 reporter line enables robust
detection of endosomal damage.
mCherry-GAL9 recruitment in response to mRNA delivery
using LNPs. The reporter cell lines were exposed to LNPs for-
mulated by microfluidic mixing of Cy5-labelled, EGFP-encoding
mRNA with lipids, using the ionisable lipid DLin-MC3-DMA
(MC3) to enable delivery9. Uptake of MC3-LNPs was observed
as a punctate Cy5 signal within wild-type and mCherry-GAL9
cells, as demonstrated after 3 h of incubation with Huh7 cells
(Fig. 3a). Quantification showed that there was no significant
difference in the number of intracellular Cy5-mRNA puncta
between wild-type and mCherry-GAL9 expressing cells
(Fig. 3b), indicating that the introduction of the mCherry-GAL9
gene did not affect cell uptake. Considerable relocalisation of the
initially diffuse cellular mCherry-GAL9 fluorescence into bright
punctate structures was observed following MC3-LNP uptake
(Fig. 3a, b) and these often co-occurred with the Cy5-mRNA
signal (Fig. 3a). This indicates that the MC3-LNPs induce
exposure of β-galactoside ligands to the cytosol permitting
mCherry-GAL9 binding. EGFP fluorescence, indicative of suc-
cessful cytosolic mRNA delivery, could also be observed from
3 h (Fig. 3a, b). No differences were observed in EGFP intensity
between wild-type and mCherry-GAL9 cells after 12 h (Fig. 3b).
Further comparison of MC3-LNP uptake and EGFP expression
in wild-type and mCherry-GAL9 Huh7 cells across time (0–14 h
post-dosing) and across a dose-range (0.1–1 µg/ml) (Supple-
mentary Fig. 3a, b) further emphasised that mCherry-GAL9
integration did not significantly alter the normal cellular pro-
cessing (uptake and mRNA delivery) of the LNPs. This indicates
that mCherry-GAL9 recruitment can be used to assess endo-
somal escape without significantly perturbing the normal traf-
ficking of LNPs.
We next examined whether the formation of mCherry-GAL9
puncta correlates with the levels of LNP exposure and uptake,
by testing a range of MC3-LNP doses across all reporter cell
lines, and as a function of incubation time, by high-content
live-cell microscopy (Fig. 3c, d). Dose-dependent increases in
Cy5-mRNA structures, induction of mCherry-GAL9 structures
and EGFP formation were observed as exemplified in Fig. 3c for
HeLa mCherry-GAL9 cells after 10 h of exposure. The Cy5-
mRNA and mCherry-GAL9 punctate structures were quantified
over 0–14 h across all reporter lines (Fig. 3d). Interestingly, the
four cell lines displayed distinct differences in both the degree
and kinetics of MC3-LNP uptake, which was also reflected in
the levels of endosomal escape. Furthermore, the cells
demonstrated variable transfection with liver lines Huh7 and
HepG2 producing the highest levels of EGFP protein (Fig. 3d,
Supplementary Fig. 4a). HepG2 cells had a notably higher level
of background autofluorescent structures in mCherry and Cy5
channels, however, LNP-induced changes were still observable
above this background level (Fig. 3d). We observed a delayed
onset and peak of Cy5 and GAL9 puncta formation between 4
and 10 h in cell lines following LNP addition, this likely
represents the time required for efficient PEG-shedding and/or
protein corona formation in the cell culture media. These
changes are prerequisites for efficient particle uptake.
Comparison of reporter lines demonstrated that Huh7 cells are
the most sensitive to endosomal escape with mCherry-GAL9
recruitment from 0.02 µg/ml and an EC50 of 0.1 µg/ml, ~2–4 fold
lower than other cell lines (Fig. 3e, Supplementary Table 1).
Correlations between Cy5-mRNA puncta and mCherry-GAL9
structures (Fig. 3f) were explored using linear regression,
revealing differences between cell lines both with respect to slope
and goodness of fit (R2= 0.573–0.9188), indicating that multiple
factors likely exist in relating the level of endosomal escape to
particle uptake (Fig. 3f, Supplementary Table 1). In general, liver
cell lines evoked higher endosomal escape for equivalent levels of
MC3-LNP uptake (Fig. 3f). Comparison of MC3-LNP uptake to
dose demonstrated less obvious differences between cell lines
(Supplementary Fig. 4b), however, liver cell lines exhibit lower
EC50 values than the other reporter lines and this may indicate
higher efficiency MC3-LNP uptake at lower particle concentra-
tions (Supplementary Table 1), possibly driven by receptor-
mediated endocytosis34.
Huh7, HepG2 and HeLa cells have very high levels of
transfection in response to MC3-LNPs, while NCI-H358 cells
had notably fewer EGFP positive cells (~50% at 0.2 µg/ml). NCI-
H358 cells often grow in clusters in standard culture conditions
and we observed that the outer ‘edge’ cells had higher LNP
uptake, substantial relocalisation of mCherry-GAL9, and there-
fore preferentially expressed EGFP (Fig. 3g). By contrast, the
MC3-LNPs appeared incapable at transfecting NCI-H358 cells in
the ‘core’ of cell clusters. This result demonstrates that the
mCherry-GAL9 recruitment assay selectively identifies individual
cells undergoing endosomal escape and delivery of mRNA to the
cytosol for translation, enabling analysis of cell-to-cell variation.
We next explored the use of small molecule kinase inhibitors
targeting mTOR, a well-established regulatory kinase of protein
synthesis, cellular growth and a negative regulator of autophagy35.
We wanted to validate that manipulating cellular translation rate
would also impact the translation of exogenous mRNA delivered
by LNPs, verifying that our reporter line can demonstrate
differences in the cellular translation rate. However, macroauto-
phagy induced by mTOR inhibition or stress responses could
potentially deliver cytosolic material such as our reporter to the
lysosome, leading to a false positive signal35. We found no
significant formation of mCherry-GAL9 structures upon induc-
tion of autophagy using dual mTOR complex (mTORC1/2)
inhibitors, Torin1 or KU0063794 (Supplementary Fig. 5a–c)
indicating autophagy induction does not lead to a false positive
signal36,37.
Co-incubation of MC3-LNPs with Torin1, KU0063794 or the
mTORC1 specific inhibitor rapamycin led to a reduction in EGFP
expression in Huh7 cells, without visibly altering Cy5-mRNA
uptake or mCherry-GAL9 recruitment (Supplementary Fig. 6a).
Quantification revealed up to a 60% reduction in EGFP
translation with Torin1 treatment compared to vehicle controls,
while no significant change was seen in particle uptake or
endosomal escape indicating the difference was due to reduced
mRNA translation (Fig. 3h). This reduction was observed with all
mTOR inhibitors (Supplementary Fig. 6b). Importantly, this
confirms that variations in protein translation rate are observable
using our mCherry-GAL9 reporter cells and that this can occur
independently of endosomal escape.
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PNPs induce mCherry-GAL9 recruitment. To demonstrate the
broad applicability of the mCherry-GAL9 recruitment assay we
examined a different nucleotide delivery system based on an
ionisable polymer series formed from DEAEMA (diethylami-
noethyl methacrylate) and BMA (butyl methacrylate). This series
varies in molecular weights but with a maintained ratio of 60:40 of
the two moieties, with or without a PEG2k first block (Fig. 4a)38,39.
We dosed mCherry-GAL9 HeLa cells with EGFP-encoding
mRNA formulated with the different polymers and monitored
for induction of endosomal escape by mCherry-GAL9 relocalisa-
tion and EGFP production (Fig. 4b–d). The polymers were able to
induce endosomal escape, but the response decreased with
increasing molecular weight (Fig. 4c). This correlated with the




























































































































































































































































































































































































































































































































































ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-01728-8
6 COMMUNICATIONS BIOLOGY |           (2021) 4:211 | https://doi.org/10.1038/s42003-021-01728-8 | www.nature.com/commsbio
PEG2k leader sequence led to a block in endosomal escape and a
consequential lack of EGFP expression (Fig. 4b–d). Examination
of effective PNPs demonstrated that the mCherry-GAL9 struc-
tures formed overlapped with Cy5-mRNA structures (Fig. 4e),
similar to what was observed for LNPs (Fig. 3a). Particles formed
from polymers lacking PEG2k were very large in size compared to
LNPs, with hydrodynamic diameters of >500 nm according to
DLS measurements (Supplementary Table 2). The large particle
size led to relatively few particles being taken up per cell and
consequently allowed comparatively simple real-time imaging of
the intracellular trafficking of individual Cy5-mRNA containing
structures over time, allowing us to capture single escape events.
Capturing the trajectory of one single PNP (Fig. 4f), we observe its
uptake into a cell and found that after 15–30min, the Cy5-mRNA
puncta became mCherry-GAL9 positive, indicating that endoso-
mal disruption has occurred. EGFP translation and cellular
fluorescence was observed after ~1 h, confirming functional
delivery of the EGFP mRNA cargo. Therefore, we are remarkably
able to resolve mCherry-GAL9 recruitment and mRNA transla-
tion down to a single endosomal release event.
Endosomal escape is enhanced when LNPs contain β-Sitosterol.
Having established the mCherry-GAL9 recruitment assay and
characterised its functional response to CADs, LNPs, and PNPs,
we returned to investigations of how the lipid composition of
LNPs influences their potency. It was recently shown that MC3-
LNPs formulated with β-sitosterol instead of cholesterol have
enhanced functional delivery of luciferase mRNA due to sus-
pected structural changes that enhance fusogenicity12,40. We
therefore compared MC3-LNPs formulated with either choles-
terol or β-sitosterol and examined their uptake, ability to induce
mCherry-GAL9 recruitment and functional delivery (i.e. EGFP
expression) across cell lines.
Whilst the Cy5-mRNA uptake was similar between the two
LNP types, the formation of mCherry-GAL9 positive structures
and subsequent EGFP expression was markedly increased in all
reporter lines following the substitution of cholesterol to β-
sitosterol (Fig. 5a). In Huh7, HeLa, and HepG2 cells, the effect
was most notable at the lower dose range (0.1–0.5 µg/ml) because
of an eventual saturation of the EGFP translation response,
which occurred at much lower concentrations for β-sitosterol
compared to cholesterol MC3-LNPs (e.g. 0.3 μg/ml vs 1 μg/ml in
HeLa cells) (Fig. 5b). For NCI-H358 cells, the positive effect of β-
sitosterol was observed across the full dose range (Fig. 5b). Time
course analysis over a period of 0–14 h was used to compare
cholesterol and β-sitosterol MC3-LNPs delivered at a dose of
0.1 μg/ml (Huh7, HeLa, HepG2) or 1 μg/ml (NCI-H358) (Fig. 5c).
Cy5-mRNA uptake was similar or mildly improved (HepG2)
whilst substantial increases in the number of mCherry-GAL9
structures upon β-sitosterol substitution were observed in all cell
lines with concomitant differences in the resulting EGFP
expression (Fig. 5c). β-sitosterol invoked mCherry-GAL9
structures across a longer time period than cholesterol particles
(HeLa/HepG2: β-sitosterol plateau at 8 h, cholesterol at 3 h).
Higher doses of LNPs (1 µg/ml) resulted in a similar mCherry-
GAL9 response in Huh7, HeLa and HepG2 cells and this in turn
yielded similar EGFP production (Supplementary Fig. 7). NCI-
H358 cells, however, still benefited from the substitution to β-
sitosterol at the highest dose of 1.5 µg/ml. Comparison of Cy5-
mRNA structures against mCherry-GAL9 structures across
doses in NCI-H358 cells confirmed that β-sitosterol induced
higher quantities of endosomal escape for equivalent particle
uptake (Fig. 5d), consistent with their suggested increased
fusogenicity12.
Taken together, these data show that LNP variants can have
similar levels of uptake, yet the levels of endosomal escape that
the LNPs elicit inside of cells can function independently of
uptake, leading to differences in subsequent mRNA delivery and
protein translation.
Integration of the mCherry-GAL9 reporter lines into an LNP
formulation screening platform. Throughout this study we have
utilised MC3:Cholesterol:DSPC:DMPE-PEG LNPs to deliver
mRNA. This LNP formulation is well-characterised and performs
well in vitro and in vivo and is a suitable tool delivery vehicle to
evaluate new assay systems6,9. However, identification of novel
particle formulations that outperform this benchmark are needed
for broad applicability of mRNA therapeutics in vivo. We
established a screening platform, integrating the use of a robotic
LNP formulation method, high-throughput particle character-
isation (for LNP size and encapsulation efficiency) and dosing of
reporter cells for live-cell imaging (Fig. 6a). We generated a panel
of 72 LNP formulations as a proof of concept, containing one of
three ionisable lipids (DLin-DMA, DLin-KC2-DMA, DLin-MC3-
DMA—hereafter denoted DMA/KC2/MC3)41,42, four phospho-
lipids (DSPC, DOPC, DSPE, DOPE), three sterols (Cholesterol,
7β-Hydroxycholesterol, 25-Hydroxycholesterol—hereafter 7B-
HC/25-HC), and two PEG-lipids (DMPE-PEG, DMG-PEG)
(Supplementary Fig. 8a), including the standard MC3-LNP for-
mulation that has been used throughout this study.
LNPs formed with the robotic system were larger at
150–400 nm (Supplementary Fig. 8b), compared to the LNPs
used in previous experiments (which were formulated using a
microfluidic device). Their size was determined using a DLS plate
reader with 90° scattering angle, which may overstate actual
particle size43. Size measurement of the same LNPs using a
Fig. 3 LNPs induce mCherry-GAL9 recruitment. a Huh7 cells ± mCherry-GAL9 reporter were dosed with 0.5 µg/ml MC3-LNPs for 3 h and imaged live,
scale bar = 20 µm, insets scale bar= 2 µm. b Quantitation of mCherry-GAL9 and Cy5-mRNA objects (3 h post-dosing) along with cellular EGFP intensity
(12 h post-dosing) shown as fold-change to the untreated wild-type control from n= 3 independent experiments ± SEM. c mCherry-GAL9 HeLa cells were
treated with a dose range of MC3-LNPs (0–0.5 µg/ml) and imaged using live-cell microscopy at 10 h post-dosing, scale bar= 20 µm. d Quantitation of
dose response in Huh7, HepG2, HeLa or NCI-H358 cells containing mCherry-GAL9 reporter across 0–14 h using 0–1 µg/ml MC3-LNPs. Values indicate
LNP uptake (Cy5-mRNA structures), endosomal escape (mCherry-GAL9 structures), mRNA delivery (EGFP fluorescence) and transfection (% EGFP
positive cells). Values were normalised to 0–1 (min-max) per replicate and combined to represent normalised means ± SEM from n= 3 independent
experiments. e Sum of GAL9 puncta per LNP dose across time course obtained in (d) was plotted against LNP dose per cell line ± SEM from n= 3
independent experiments. Four-parameter logistic curve with variable slope fitted for each cell line to mean values to obtain EC50 of LNP dose for GAL9
puncta induction. f Cy5 puncta were plotted against mCherry-GAL9 puncta across time course obtained in (d) per cell line, linear regression was fitted for
each. Values obtained and fits for e, f are shown in Supplementary Table 1. g mCherry-GAL9 NCI-H358 cells dosed with 0.5 µg/ml MC3 and imaged after
10 h of incubation, scale bar= 20 µm, insets= 10 µm. h mCherry-GAL9 Huh7 cells co-dosed with 0.5 µg/ml MC3-LNP and 0.3 µM Torin1, 0.3 µM
KU0063794, 0.1 µM Rapamycin or DMSO control. Quantitation of indicated structures/cell intensity. Values represent normalised means from n= 3
independent experiments ± SEM. Significance was determined by two-way ANOVA followed by Dunnett’s post-test to the DMSO control where *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 and n.s. not significant.
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Malvern Zetasizer cuvette-based instrument with 173° scattering
angle yielded Z-average sizes ~25% smaller (Supplementary
Fig. 8c) confirming this view, but LNPs were nevertheless larger
than NanoAssemblr formed LNPs. In addition, robotic LNP
formulation resulted in poorer mRNA encapsulation (30–60%)
than NanoAssemblr formed particles (~95–99%) (Supplementary
Fig. 8b). Using this screening platform, we exposed mCherry-
GAL9 Huh7 cells to LNPs and monitored particle uptake,
mCherry-GAL9 recruitment, EGFP expression and percentage of
cellular transfection by time-lapse microscopy as established
earlier (Fig. 3d). For easier comparison between LNP formula-
tions, a heatmap was generated for each assayed parameter (Cy5-
mRNA uptake, GAL9 recruitment, EGFP expression, percent
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Fig. 4 mCherry-GAL9 responds to polymeric nanoparticles. a Overview of polymer names and compositions. Polymers are comprised of DEAEMA (60%)
and BMA (40%) at variable lengths ± PEG2k first block. b Representative images of HeLa mCherry-GAL9 cells dosed with 1 µg/ml of indicated polymers in
serum-free media and imaged by live-cell microscopy, scale bar= 20 µm. c Quantitation of cells treated as in (b) for mean mCherry-GAL9 structures or
d mean EGFP expression both ± SEM from n= 3 independent experiments. e Representative images of HeLa mCherry-GAL9 cells treated with 1 µg/ml of
EB10250, EB17610 or PBS control. Scale bar= 20 µm, insets= 5 µm. f Images of HeLa mCherry-GAL9 cells dosed with EB10250 polymer at 1 µg/ml in
serum-free media and imaged live. Arrows indicate a single Cy5-mRNA particle taken up by a HeLa cell and undergoing endosomal escape, scale bar=
20 µm. Asterix indicates a non-specific autofluorescent signal present in all channels.
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Fig. 5 β-Sitosterol modifies endosomal escape rate. a Huh7, HepG2, HeLa and NCI-H358 mCherry-GAL9 cells were dosed at indicated concentrations of
MC3-LNPs formulated with cholesterol or β-sitosterol. Images are representative of 14 h post-dosing. Scale bar= 20 µm. b Comparison of cell EGFP
fluorescent intensity at 14 h after incubation with Cholesterol or β-sitosterol particles in Huh7, HeLa, HepG2 and NCI-H358 cells across 0.1–1.5 µg/ml
doses. Values represent normalised EGFP intensity ± SEM from n= 3 independent experiments. c Quantitation of (a) examining the formation of Cy5
positive structures, mCherry-GAL9 structures and EGFP fluorescence per cell over time. Values represent normalised means ± SEM from n= 3
independent experiments. Significance was determined in (b, c) for full 0–14 h time courses by two-way ANOVA followed by Tukey’s multiple comparison
test where *p < 0.05, **p < 0.01 ***p < 0.001, ****p < 0.0001 and ns not significant. d Comparison of total Cy5 or GAL9 puncta over time obtained from (c)
for cholesterol or β-sitosterol particles in NCI-H358 cells. Linear regression carried out and R2 values displayed on the graph.
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In this screen, we explored cholesterol derivatives, expanding
from the analysis of β-sitosterol (Fig. 5). We substituted
cholesterol to 7B-HC or 25-HC, a hydroxyl modification of
cholesterol ring B or the tail region respectively. The character-
istics of the 7B-HC LNPs were similar to cholesterol LNPs,
however, 25-HC particles suffered from poorer encapsulation
efficiencies (average 29% vs 43%, Fig. 6c—left panel). Cellular
uptake of 7B-HC and 25-HC particles was severely ablated
(Fig. 6b, c). Despite this, there was still recruitment of mCherry-
GAL9, but interestingly this did not result in functional mRNA
delivery, as evidenced by the near lack of EGFP expression and
low transfection level. This suggests additional parameters affect
to what extent the delivered mRNA can be utilised by the cell and
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hinders protein translation. Subsequent data comparisons, for
this reason, focus solely upon LNPs containing cholesterol.
DMA and KC2 are ionisable lipids that have similar pKas of 6.7
and 6.8 respectively (~6.44 for MC3) but have been reported to
have ~20-fold range in potency in mice as determined by Factor
VII ED50 (1 mg/kg (DMA) vs 0.1 mg/kg (KC2) 0.05 mg/kg
(MC3))9,42. Consistent with this, the substitution of MC3 to
DMA or KC2 led to reduced particle uptake, reduced levels of
endosomal escape and consequently markedly reduced levels of
EGFP expression (Fig. 6b, d). However, DMA and KC2 LNPs,
whilst resulting in similar levels of uptake, perform differently
with respect to their capacity to induce endosome damage
(Fig. 6d), with KC2 having enhanced endosomal escape potency
and thereby outperforming DMA in terms of protein expression
and transfection efficiency.
Finally, we examined differences in particles containing either
DMG-PEG2k or DMPE-PEG2k. Whilst both contain a C14-acyl
chain and PEG2k, DMPE contains a phosphate group giving the
overall molecule a negative charge compared to DMG that is
neutral. Substitution to DMG-PEG2k resulted in reduced uptake
and slower kinetics, lower endosomal escape induction and
ultimately impaired EGFP production across all particles
surveyed (Fig. 6b, e). It has been shown that the half-life of
DMPE-PEG on nanoparticle surfaces is shorter than DMG-
PEG13 and this may account for some of the changes observed. In
addition, particle charge variance may also lead to differential
interactions with serum proteins that are important for cellular
uptake and/or endosomal escape13. Representative microscopy
images demonstrating changes to key particle components on the
uptake, GAL9 recruitment and EGFP translation are shown in
Supplementary Fig. 9.
Altogether, the screen presented in Fig. 6 illustrates that LNPs
with similar physical properties such as size, PDI and encapsula-
tion but formed from different lipids can demonstrate great
variation in terms of how they are taken up by cells and are able
to deliver mRNA. Integration of the mCherry-GAL9 reporter into
a screening platform with multiple cellular read-outs have
allowed us to probe in greater detail to which delivery step a
certain lipid alteration can modulate LNP potency and highlights
the benefits of utilising such a reporter system for deriving greater
insights into nanoparticle function.
Discussion
In this work, we have demonstrated a comprehensive system for
the monitoring of nanoparticle trafficking from uptake, to
endosomal escape, and to protein translation within a single
microscopy assay and established a screening platform by inte-
grating the assay with robotic formulation and high-throughput
biophysical analysis of LNPs.
The benefits of such an assay are clear in that they enable
comparison of nanoparticles across multiple relevant parameters
to ascertain mechanistically why one particle formulation may
outperform another, an explanation that is often absent if simply
observing protein translation. By automated formulation of a
panel of 72 LNPs, we were able to examine the relative con-
sequences of substitution of each lipid component. This approach
can highlight the general effect of component substitution but
reduces the reliance on using a single LNP to make the decision of
efficacy. Our results indicated that a particle formulated using
DLin-MC3-DMA, Cholesterol, and DMPE-PEG would perform
best across uptake and endosomal escape parameters. Indeed,
particles comprised of these three components and a variable
phospholipid were the highest performing particles in our screen.
Whilst this replicates our current understanding of well-
performing LNP formulation, our study importantly demon-
strates and validates that this assay can be used to survey a wider
chemical space of poorly explored lipids, with a rich information
read-out. This will make it possible to identify LNP formulations
that outperform benchmark LNPs or can achieve the same level
of delivery at lower dosing requirements.
Our analysis of substitution of cholesterol to β-sitosterol within
LNPs confirms that particle uptake and endosomal escape can act
independently of one another and highlights the importance of
understanding and optimising both parameters during the design
of next-generation LNPs. Cellular uptake of these particles was
similar but endosomal escape was strongly improved by switching
to β-Sitosterol, consistent with a recent report that β-sitosterol
particles have a multi-faceted structure that may directly mod-
ulate endosomal fusion40. Even so, little is known about if there
are fundamental underlying differences in the endosomal com-
partments that particles are taken up in or whether there are
other differences in the protein corona formed that may alter
particle fusion/endosomal escape properties. Interestingly, sub-
stitution to β-sitosterol did not significantly increase the max-
imum amount of EGFP protein attainable suggesting natural
limits exist on how much exogenous mRNA can be utilised by
cells. Further benefits may therefore be obtainable by modulating
cellular translation rates or mRNA cargo sequences to enhance
ribosome docking and translation. The relative benefit of
achieving enhanced endosomal escape may not necessarily be
through higher protein expression, instead the benefits may come
from lower dosing requirements that thereby reduce the cost of
mRNA therapies and the risk of toxic effects, in particular from
the drug vehicle itself.
We were also able to induce a GAL9 response without a
delivery vehicle but by using CADs such as UNC2383. The
response to CADs appeared phenotypically similar to that
induced by LNPs or PNPs and is consistent with the compounds
proven capability to deliver oligonucleotides29. However, the
cellular toxicity associated with these compounds tentatively
suggests underlying differences in the process inducing GAL9
recruitment and may suggest a more severe endolysosomal
damaging approach rather than the fusion that is anticipated with
ionisable LNPs. Variation in the size of the mCherry-GAL9
structures generated by UNC2383 and chloroquine suggests
underlying differences in the endolysosome membrane com-
partments targeted by CADs, this may correspond with differ-
ences in utility for aiding oligonucleotide delivery. Future studies
are required to evaluate whether combining CADs with
Fig. 6 Use of mCherry-GAL9 reporter line with automated particle formulation. a Overview of experimental approach. particles are formed by automated
pipetting in a plate-based format and feed directly into plate-based assays for particle size determination by dynamic light scattering (DLS), encapsulation by
ribogreen integration and for dosing mCherry-GAL9 reporter cells directly. b Heatmap summary of LNP formulation variation data representing normalised
Cy5-mRNA uptake, mCherry-GAL9 puncta, EGFP fluorescence and % EGFP positive cell values at 14 h post-dosing. Red square indicates standard
composition of particles used in rest of manuscript. c–e Overview of particle characteristics and kinetic results obtained with the screening approach looking
at comparisons of particles based upon variable components. Values plotted are mean normalised values ± SEM c Sterol modified particles, n= 24 LNPs per
group from n= 4 independent experiments. d Ionisable lipid modified, only data with cholesterol particles shown, n= 8 per group from n= 4 independent
experiments e PEG-lipid modified, only data with cholesterol particles shown, n= 12 per group from n= 4 independent experiments.
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LNPs/PNPs is a viable strategy to enhance cellular delivery of
mRNA, as previously shown with small oligonucleotides. Recent
work has suggested that some CADs are able to induce endoso-
mal rupture and enhance nanoparticle-mediated delivery, but this
is dependent upon nanoparticle formulation44. In addition, the
rapid and acute onset of GAL9 recruitment with UNC com-
pounds suggests accurately synchronising compound dosing with
particle uptake is likely to be critical. We have shown that
mCherry-GAL9 cellular models boast a high Z’ factor, making
this assay amenable for subsequent high-content screening for
novel CADs or LNPs that are potent inducers of endosomal
rupture and that will allow us to explore this point further.
Not all delivery vehicles induce Galectin recruitment responses.
Recently, extracellular vesicles were demonstrated to act in a
GAL3-independent manner, however, it should be noted that
GAL3 is a weaker identifier of endosomal damage than
GAL924,45. It will be interesting to examine whether other
emerging delivery vectors for oligonucleotides such as den-
drimers, particle modifications with cell-penetrating peptides or
the use of viral-like particles invoke GAL9 recruitment responses
that are similar to those induced by LNPs. Readout of endosomal
escape with mCherry-GAL9 recruitment strongly correlates with
the translation of cargo mRNA and is therefore an excellent
predictor for nanoparticle efficacy. However, GAL9 recruitment is
not always indicative of successful protein production as trans-
lation can still be decoupled from endosomal escape as demon-
strated by the utilisation of mTOR inhibitors or the substitution
of cholesterol for 7B-HC/25-HC in LNPs. Hydroxycholesterols
have previously been shown to inhibit mTOR signalling and
therefore protein translation46, but could also potentially influ-
ence mRNA-lipid complexation and hinder cytosolic mRNA
release.
By integrating the mCherry-GAL9 reporter into multiple cell
lines, we can also begin to explore cell to cell differences in
response to LNPs. Our study showed that liver-derived cell
models demonstrated greater sensitivity to endosomal disruption
from MC3-LNPs than non-liver cell models without equivalent
differences in the level of particle uptake, providing a more
detailed understanding to the observation by Sayers et al. that
LNPs are differently effective in liver-derived Huh7 compared to
lung-derived NCI-H35847. Examination of a wider range of LNP
formulations and cationic lipids will be important to determine
whether this is an intrinsic sensitivity of these cell models to
nanoparticle delivery or whether this is indicative of a
composition-driven LNP selectivity for certain cell types. Simi-
larly, integrating the mCherry-GAL9 into a broader range of
cellular models will be important for screening particle for-
mulations for the identification of parameters important for
selective uptake to ultimately facilitate selective organ targeting
in vivo.
By improving our understanding of LNP characteristics that
are critical to achieve particle uptake and endosomal escape
across cellular models, we can ideally achieve therapeutic doses
using lower amounts of potentially immunogenic lipid carriers
and reduce the costs for future potential treatments. Identification
of novel particle formulations will undoubtably require con-
siderable efforts to screen nanoparticle variations in a robust
manner, we believe this assay forms a fundamental basis for
future screening endeavours to progress the development of drug
delivery systems.
Methods
Materials. Cholesterol (C8667), DOPC (P6354) and Chloroquine (C6628) were
obtained from Sigma Aldrich. DSPC (LP-R4-076), DOPE (LP-R4-069) were from
Merck-Millipore. 7β-hydroxycholesterol (700035P), 25-hydroxycholesterol
(700019P), β-sitosterol (700095P) and DSPE (850715P) were from Avanti Polar
Lipids. DMG-PEG2k (GM-020) and DMPE-PEG2k (PM-020CN) were from Nof
America Corporation. Cationic lipids DLin-DMA, DLin-KC2-DMA, DLin-MC3-
DMA and small molecules KU0063794, Rapamycin, Torin1, UNC2383, UNC4167,
UNC10217938A were chemically synthesised.
Cell line maintenance and generation of GAL9 reporter. HeLa (CCL-2), HepG2
(HB-8065) and NCI-H358 (CRL-5807) cells were purchased from ATCC whilst
Huh7 (Riken - RCB1366) were a kind gift from Prof. Samir El-Andaloussi (KI,
Stockholm), all cell lines were authenticated by STR profiling and tested negative
for mycoplasma contamination. Cells were maintained at 37 °C in a humidified
incubator in a complete media of DMEM+Glutamax (Huh7, HeLa, HepG2) or
RPMI+Glutamax (NCI-H358 cells) both supplemented with 10% foetal
bovine serum.
Stable cells expressing mCherry-GAL9 were generated by knock-in at the
AAVS1 locus. Cells were seeded at 2 × 105 cells/well (12-well) and transfected with
mCherry-GAL9 reporter:AAVS1 zinc-finger nuclease (1:9) using FuGENE HD
transfection reagent (Promega) as per manufacturer’s instructions. Cells were
incubated for 48 h before the addition of 1 µg/ml Puromycin to select for stably
integrated cells. Stable cells were subsequently sorted into similar expression pools
by flow cytometry.
Imaging experiments and quantitation. Cells were seeded into 384-well Cell-
Carrier Ultra plates (PerkinElmer: 6007558) in complete media a minimum of 16 h
prior to treatment. Hoechst 33342 was added to cell culture medium at 0.5 µg/ml a
minimum of 1 h prior to imaging experiments to evenly stain nuclei prior to
experiment start points. Nanoparticle or small molecules were first dispensed into a
384-well source plate (Greiner: 781280) containing appropriate complete media+
0.5 µg/ml Hoechst by using an Echo 655T acoustic dispenser (Labcyte). At the
experimental start point, the media on cells was removed and replaced directly by
media containing LNPs/small molecules from the source plate using a Bravo liquid
handling robot (Agilent). The cell plate was then moved to the microscope and
imaged immediately. Live-cell experiments were carried out within a humidified
imaging chamber maintained at 5% CO2 with a CV7000 (Yokogawa) spinning disk
confocal microscope utilising a 20x objective (NA 0.75). Images were obtained
using a 405 nm laser (BP445/45 nm), 488 nm laser (BP522/35), 561 nm laser
(BP600/37) or 640 nm laser (BP676/29) for relevant fluorophores. For microscopy
time-course measurements, the same fields of view were imaged over time that had
received the experimental treatment noted in the figure. Images were processed and
analysed for relevant features and parameters indicated in figures utilising
Columbus image-analysis software (Perkin Elmer, v2.9.0). Briefly, spots were
identified using maximum intensity projection fluorescence images. Cells were
identified using Hoechst 33342 for nuclei detection and combined mCherry-GAL9
and EGFP signal (where appropriate) for individual cell boundaries. Within
individual cell regions of interest, spot populations were quantified using a ‘Find
spots’ building block within Columbus software that identifies punctate structures
with relative intensities higher than local background cellular intensity, no limits
were placed on max puncta size. Data were exported and handled in Spotfire
(Tibco, v10.3), in many cases numerical values obtained were normalised for
combining between experimental replicates. Data were exported and plotted with
Prism (Graphpad, v8.0.1).
PCR and droplet digital PCR. DNA was extracted from wild-type (WT) and GAL9
transgenic cell pools using QuickExtract™ DNA extraction solution (Lucigen),
according to the manufacturer’s instructions. Briefly, extraction solution was added
to cell pellets, followed by samples vortexing and incubation at 65 °C for 6 min.
Samples were vortexed again and incubated at 98 °C for 2 min. For ddPCR, the
same amount of DNA (50 ng) for all samples was mixed with ddPCR supermix for
probes, puromycin-FAM primers/probe mix, AP3B1-HEX primers/probe mix (all
from Bio-Rad), and Hind III 5U (New England BioLabs Inc.) restriction enzyme.
Samples were incubated for 10 min at room temperature (RT) for DNA frag-
mentation. PCR droplets were generated on an Automatic Droplet Generator using
oil for probes (all from Bio-Rad). Target genes were amplified on a C1000 thermal
cycler (Bio-Rad) according to the following conditions: 95 °C for 10 min, followed
by 40 cycles of template denaturation at 94 °C for 30 s, and annealing and extension
at 57 °C for 1 min, with a temperature ramping ratio of 2 °C/s, with a final incu-
bation step at 98 °C for 10 min. PCR droplets were analysed on a QX200 droplet
reader equipped with QuantaSoft software v.1.7.4 (Bio-Rad). Populations of
fluorescent droplets were identified as depicted in Supplementary Fig. 2 and the
average copy number of target gene insertions per cell was calculated using the
Copy Number Variation algorithm, considering a 2x ploidy for HepG2 and Huh7
cell lines, and a 3x ploidy for HeLa and NCI-H358 cell lines, and normalised to the
copy number of the reference gene AP3B1. For endpoint PCR, DNA was first
further purified by mixing with ice-cold ethanol 99,9% in a ratio 1:3 (v/v), followed
by overnight incubation at −20 °C, and then by washing with ethanol 70%.
Samples were dried at RT and DNA dissolved in nuclease-free water. Purified DNA
(100 ng) was then mixed with Phusion Flash PCR master mix (ThermoFisher
Scientific) and primers spanning the AAVS1 locus and the donor construct, fol-
lowed by incubation on a C1000 thermal cycler (Bio-Rad) according to the fol-
lowing conditions: 98 °C for 10 sec, followed by 35 cycles of template denaturation
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at 98 °C for 1 s, annealing at 54 °C for 5 s and extension at 72 °C for 15 s, with a
final incubation step at 72 °C for 1 min. Amplicons were then resolved in a 2%
agarose E-gel, using TrackiT 1 Kb plus DNA ladder (all from ThermoFisher Sci-
entific), followed by gel imaging on a Gel-Doc system (Bio-Rad).
Fluorescence-activated cell sorting (FACS). WT and mCherry-GAL9 reporter
cells were grown and expanded until 80% confluency. Cells were washed twice with
PBS, detached with TrypLE Express (10 min, 37 °C), resuspended in FACS buffer
(5% FBS in PBS) and filtered in FACS tubes using a 35 µm mesh (Falcon). Cell
sorting was performed on a FACSAriaTM III cytometer (from BD Instrument),
using the BD FACSDiva Software. For each cell type, WT cells were used to set up
the voltage of the forward scatter (FSC) and side scatter (SSC) as well as to adjust
the autofluorescence level in the mCherry channel. Debris was excluded by plotting
the FSC vs SSC with all events and gating for living cells, and cell aggregates
(doublets/clusters) were excluded by plotting the SSC-height vs SSC-area with
living cells and gating for single cells. mCherry-positive GAL9 reporter cells were
sorted in bulk according to two fluorescence intensity levels. Following sorting,
cells were spun down (200 g, 5 min at RT) to remove excess FACS buffer and then
grown for a week in presence of 1% penicillin-streptomycin. Antibiotics-free cul-
ture medium was used for cell experiments.
Western blotting. Cell pellets (5 × 106 cells) were lysed in RIPA buffer (Thermo
Fisher Scientific) supplemented with protease inhibitors (Sigma-Aldrich) for
15 min on ice. Total protein content was determined using the Qubit protein assay
kit (Thermo Fisher Scientific) following the manufacturer´s protocol. Protein
lysates (40 µg/lane) were separated by SDS-PAGE and transferred to poly-
vinylidene fluoride membranes (BioRad). Membranes were blocked with Intercept
(TBS) blocking buffer (LI-COR) for 1 h at RT and incubated with primary anti-
bodies mCherry (E5DF8, #43590) and β-Tubulin (9F3, #2128) (Cell Signalling
Technologies) diluted 1:1000 in blocking buffer at 4 °C overnight. Membranes were
washed three times with 0.1% TBS-Tween and incubated for 1 h at RT with IRDye
800CW goat anti-rabbit IgG cat# 926–32211 (LI-COR) diluted 1:20,000 in 0.1%
TBS-Tween. Following washes, membranes were visualised with the Odyssey CLx
imaging system and processed in Image Studio (v4.0, LI-COR).
Formation of LNPs (NanoAssemblr). DLin-MC3-DMA cholesterol or β-
sitosterol containing LNPs were formulated using a NanoAssemblr (Precision
NanoSystems) by microfluidic mixing chip. Briefly, lipids were prepared in Ethanol
at a ratio of 50:38.5:10:1.5 (MC3:Sterol:DSPC:DMPE-PEG2000) at a 10:1 (w/w)
Lipid:mRNA cargo, N:P ratio= ~3:1. mRNA cargo encoding for EGFP was pre-
pared at a 4:1 ratio (Unlabelled:Cy5 labelled – TriLink: L7201/7701) in 50 mM
Citrate pH 3 buffer (TekNova: Q2445). Lipid and mRNA containing solutions were
mixed 3:1 (Citrate:Ethanol) at a constant flow rate of 12 ml/min to form nano-
particles. Particles were dialysed overnight into PBS pH 7.4 at 4 °C and sterile
filtered using a 0.23 µm filter. Characteristics of LNP batches used in this study are
shown in Supplementary Table 2.
Formation of LNPs (automated pipetting). Robotic formulation of particles was
achieved utilising a Bravo liquid handling robot utilising VWorks software
(v12.2.0.1306, Agilent). Particles were prepared at a ratio of 50:38.5:10:1.5 (Cationic
Lipid:Sterol:Phospholipid:PEG-Lipid) at a 20:1 (w/w) lipid:mRNA cargo, N:P ratio
= ~6:1. 7.5 µl of each lipid component was combined per well to a final volume of
30 µl. mRNA cargo encoding for EGFP was prepared at a 4:1 ratio (Unlabelled:Cy5
labelled – TriLink: L7201/7701) in 50 mM Citrate pH 3 buffer (TekNova: Q2445) at
30 µl per well (122 µg/ml). 10 µl of the lipid-ethanol mix was added directly to
mRNA mix and pipetted up and down 10 × 20 µl. An equal volume (40 µl) of PBS
pH 7.4 was then added to the mRNA/lipid and mixed a further 5 × 20 µl and then
incubated at 4 °C overnight prior to usage.
Formation of PNPs (automated pipetting). Polyplexes were prepared utilising a
Bravo robot as for LNPs (above). 20 µl of 50 mM citrate pH 3 (TekNova #Q2445)
buffered mRNA (4:1 GFP:Cy5 –TriLink CleanCap mRNA L-7201/L-7701) (100 μg/
ml) was injected into wells (Greiner V-bottom #781280) that contain 20 μL of the
desired polymer solution at an amine:phosphate ratio of 8:1 assuming 50% amines
charged per polymer. After addition of the RNA solution, polyplex suspensions
were mixed through 10 × 15 μl mix steps and incubated at RT for 30 min prior to
addition of an equal volume (40 μl) 1 M Tris-HCl pH 8 (TekNova #T1080).
Polyplexes were mixed 5 × 15 μl before moving to 4 °C for 16 h prior to use.
Particle characterisation – DLS and encapsulation. Size (Diameter, Z-average) of
particles and polydispersity index (PDI) was determined by dynamic light scat-
tering utilising a Malvern Zetasizer (λ= 633 nm, scattering angle= 173°) for
particles formed by NanoAssemblr or a Malvern Zetasizer APS (λ= 832 nm,
scattering angle= 90°) for particles formed by pipetting. In both cases standard
viscosity and refractive index values for pure water at 25 °C, 0.8872 mPa and 1.33
respectively, were used for data analysis within Zetasizer software (v7.12, Malvern).
Ribogreen dye (Thermo Fisher Scientific) was used according to manufacturer’s
guidelines ± 1% Triton to ascertain encapsulated mRNA by comparison to a
relevant mRNA standard curve.
Statistics and reproducibility. Statistical testing was carried out in Prism (Graph-
pad, v8.0.1) with relevant multiple comparisons and post-test where appropriate. No
formal sample-size calculation was performed and no randomisation strategy was
applied. For microscopy experiments, data were collected for as many fields of view as
possible whilst maintaining time-points required for time-course experiments.
Technical duplicates within each experiment were obtained as a minimum. No data
were excluded from the analysis and all reported results were replicable. Statistical
testing was carried out upon a minimum of three independent experimental repli-
cates. See figure legends for full details of replicates, statistical testing and significance.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The source data underlying all quantitative figures are provided as Supplementary
Data 1. All data supporting the findings of this study are available from the
corresponding author upon reasonable request.
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